- Email: [email protected]
New Bordetella pertussis vaccine; with purified filamentous hemagglutinin, detoxified lymphocytosis promoting factor and 69-kDa outer membrane protein antigen
Patent Report
of B. dermatitidis after freezing. Alternatively, the protein may be produced synthetically or the gene encoding the protein can be located, cloned and expressed. The WI-1 protein is used to detect antibodies to B. dermatitidis and for the production of antibodies. It is high specific and can be used to detect blastomycosis by RIA, with no cross-reactivity with patients with histoplasmosis, coccidoidmycosis, sporotrichosis or candidiasis. The WI-1 protein can also be used in a vaccine to inhibit infection by B. dermatitidis. In an example, 40 mg of crude extract derived by freezing ( - 2 0 ° C ) and thawing B. dermatitidis ATCC 60636 was subjected to SDS-PAGE to produce a 120 kDa protein. This was used to produce and detect WI-1 antibody. 085-92
New Bordetella pertussis vaccine; with purified filamentous hemagglutinin, detoxified lymphocytosis promoting factor and 69-kDa outer membrane protein antigen Am. Cyanamid Aus 9180 335; 16 January 1992 A new pertussis vaccine comprises filamentous hemagglutinin (FHA), detoxified lymphocytosis promoting factor (LPF) and a 69-kDa outer membrane protein of Bordetella pertussis, where the three antigens are individually purified prior to combination into the vaccine (preferably at 4:2:1). The vaccine may also contain one or more fimbrial agglutinogens from B. pertussis, and/or a 30-kDa outer membrane protein. Other B. pertussis structural components, such as polysaccharides, lipopolysaccharides, lipids, proteins, glycoproteins and lipoproteins, may also be included. The antigens are conjugated to each other, or to other components. A multivalent vaccine in combination with non-pertussis components, e.g. from inactivated poliovirus, Haemophilus influenzae, Haemophilus polyribosylphosphate-protein conjugate, Neisseria meninoococcus, Pneumococcus sp., hepatitis B virus, Corynebacterium diphtheriae diphtheria toxoid or Clostridium tetani tetanus toxoid, is also new. The new vaccine does not contain undesired components, e.g. endotoxin, avoids side-effects, and has improved antigen presentation and efficacy. 086-92
Vaccine for protection of poultry against Haemophilus paragallinarum infection; recombinant 38 kDa outer membrane protein production for use in fowl recombinant vaccine Akzo Eur 475 478; 18 March 1992
The following are claimed: i. a vaccine for the protection of fowl against Haemophilus paragallinarum (Hp) infection, characterized in that it is free from cells and filamentous material and is derived from a membranous fraction of Hp cells comprising an outer membrane protein (OMP) of 38 kDa; ii. Hp antigenic material characterized in that it is the membranous fraction of Hp cells comprising the 38 kDa O M P ; and iii. antibody or antiserum immunoreactive with the Hp antigenic material as in (ii). The 38 kDa O M P can be obtained by chemical synthesis, purification from Hp cells or by recombinant DNA technology. In the latter case, DNA sequences encoding the OMP are identified by screening a gene bank of Hp DNA and ligated to various plasmids resulting in a recombinant vector which can be used for the transformation of a suitable bacterium or mammal cell culture. Transformed hosts are used to produce recombinant 38 kDa O M P which is then incorporated into a vaccine. The antigen is highly protective against Hp infection. Antiserum and antibodies can be used for passive immunization of birds and for immunological diagnosis of birds infected with Hp. 087-92
New vaccine against invasive amoebiases; contains immunodominant surface antigen of Entamoeba histolytica obtained by gene cloning; monoclonal antibody production and use in diagnosis of infection Univ. Calif. World 9203 457 ; 5 March 1992 The following are clained : a vaccine against invasive amoebiasis which includes the 125 kDa extracellular immunodominant surface antigen (I) of Entamoeba histolytica; DNA encoding this protein; cells carrying this DNA; a diagnostic kit containing the DNA for detection of an E. histolytica surface antigen gene ; purified (I), including a fusion protein including (I); monoclonal antibody FA7 that specifically binds (I); a protein having an epitope specifically bound by FAT; a diagnostic kit containing FA7 for detection of (I); a method of vaccinating a susceptible host to confer immunity against invasive amoebiasis by administration of (I), prior to or after amoeba infection ; a method for treating an animal infected with Entamoeba involving injection of (I) to induce an immune response; a method of immunizing an animal against E. histolytica infection by introduction of (I) to induce production of IgA and interfere with amoeba reproduction ; and a method for detecting pathogenic amoeba in a biopsy sample by using an antibody specific for an epitope characteristic of the pathogenic amoeba. 088-92
Vaccine, Vol. 10, Issue 11, 1992 807
of B. dermatitidis after freezing. Alternatively, the protein may be produced synthetically or the gene encoding the protein can be located, cloned and expressed. The WI-1 protein is used to detect antibodies to B. dermatitidis and for the production of antibodies. It is high specific and can be used to detect blastomycosis by RIA, with no cross-reactivity with patients with histoplasmosis, coccidoidmycosis, sporotrichosis or candidiasis. The WI-1 protein can also be used in a vaccine to inhibit infection by B. dermatitidis. In an example, 40 mg of crude extract derived by freezing ( - 2 0 ° C ) and thawing B. dermatitidis ATCC 60636 was subjected to SDS-PAGE to produce a 120 kDa protein. This was used to produce and detect WI-1 antibody. 085-92
New Bordetella pertussis vaccine; with purified filamentous hemagglutinin, detoxified lymphocytosis promoting factor and 69-kDa outer membrane protein antigen Am. Cyanamid Aus 9180 335; 16 January 1992 A new pertussis vaccine comprises filamentous hemagglutinin (FHA), detoxified lymphocytosis promoting factor (LPF) and a 69-kDa outer membrane protein of Bordetella pertussis, where the three antigens are individually purified prior to combination into the vaccine (preferably at 4:2:1). The vaccine may also contain one or more fimbrial agglutinogens from B. pertussis, and/or a 30-kDa outer membrane protein. Other B. pertussis structural components, such as polysaccharides, lipopolysaccharides, lipids, proteins, glycoproteins and lipoproteins, may also be included. The antigens are conjugated to each other, or to other components. A multivalent vaccine in combination with non-pertussis components, e.g. from inactivated poliovirus, Haemophilus influenzae, Haemophilus polyribosylphosphate-protein conjugate, Neisseria meninoococcus, Pneumococcus sp., hepatitis B virus, Corynebacterium diphtheriae diphtheria toxoid or Clostridium tetani tetanus toxoid, is also new. The new vaccine does not contain undesired components, e.g. endotoxin, avoids side-effects, and has improved antigen presentation and efficacy. 086-92
Vaccine for protection of poultry against Haemophilus paragallinarum infection; recombinant 38 kDa outer membrane protein production for use in fowl recombinant vaccine Akzo Eur 475 478; 18 March 1992
The following are claimed: i. a vaccine for the protection of fowl against Haemophilus paragallinarum (Hp) infection, characterized in that it is free from cells and filamentous material and is derived from a membranous fraction of Hp cells comprising an outer membrane protein (OMP) of 38 kDa; ii. Hp antigenic material characterized in that it is the membranous fraction of Hp cells comprising the 38 kDa O M P ; and iii. antibody or antiserum immunoreactive with the Hp antigenic material as in (ii). The 38 kDa O M P can be obtained by chemical synthesis, purification from Hp cells or by recombinant DNA technology. In the latter case, DNA sequences encoding the OMP are identified by screening a gene bank of Hp DNA and ligated to various plasmids resulting in a recombinant vector which can be used for the transformation of a suitable bacterium or mammal cell culture. Transformed hosts are used to produce recombinant 38 kDa O M P which is then incorporated into a vaccine. The antigen is highly protective against Hp infection. Antiserum and antibodies can be used for passive immunization of birds and for immunological diagnosis of birds infected with Hp. 087-92
New vaccine against invasive amoebiases; contains immunodominant surface antigen of Entamoeba histolytica obtained by gene cloning; monoclonal antibody production and use in diagnosis of infection Univ. Calif. World 9203 457 ; 5 March 1992 The following are clained : a vaccine against invasive amoebiasis which includes the 125 kDa extracellular immunodominant surface antigen (I) of Entamoeba histolytica; DNA encoding this protein; cells carrying this DNA; a diagnostic kit containing the DNA for detection of an E. histolytica surface antigen gene ; purified (I), including a fusion protein including (I); monoclonal antibody FA7 that specifically binds (I); a protein having an epitope specifically bound by FAT; a diagnostic kit containing FA7 for detection of (I); a method of vaccinating a susceptible host to confer immunity against invasive amoebiasis by administration of (I), prior to or after amoeba infection ; a method for treating an animal infected with Entamoeba involving injection of (I) to induce an immune response; a method of immunizing an animal against E. histolytica infection by introduction of (I) to induce production of IgA and interfere with amoeba reproduction ; and a method for detecting pathogenic amoeba in a biopsy sample by using an antibody specific for an epitope characteristic of the pathogenic amoeba. 088-92
Vaccine, Vol. 10, Issue 11, 1992 807